Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992153 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4MAPTMEN1KMT2A | |
| SCHEMBL356174 | 0.88 | TLR7 (0.40) | ITGB1ITGA4MAPTMEN1KMT2A | |
| SCHEMBL16629048 | 0.87 | KDM4E (0.38) | MAPTMEN1KMT2AJAK2CASP3 | |
| SCHEMBL19864295 | 0.87 | MEN1 (0.41) | MAPTMEN1KMT2ALMNAJAK2 | |
| SCHEMBL18188914 | 0.87 | HDAC4 (0.46) | ITGB1ITGA4MAPTELANECASP3 | |
| SCHEMBL16583378 | 0.85 | PTGS2 (0.47) | ITGB1ITGA4MAPTMEN1KMT2A | |
| SCHEMBL10163665 | 0.83 | RXFP1 (0.55) | MAPTMEN1KMT2ALMNARXFP1 | |
| SCHEMBL1752734 | 0.82 | MEN1 (0.53) | MAPTMEN1KMT2ALMNA | |
| SCHEMBL11901432 | 0.82 | CXCL8 (0.42) | MAPTMEN1KMT2ALMNAGAA | |
| SCHEMBL20061313 | 0.81 | ITGB1 (0.43) | ITGB1ITGA4MAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828377-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775844-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-08-13 | — | — | US | disclosed |
| WO-2015061204-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015051241-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051244-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2013116562-A1 | COMPOSITIONS AND METHODS OF TREATING A DISEASE WITH (S)-4 AMINO-6-((1-(5-CHLORO-4-OXO-3-PHENYL-3,4-DIHYDROQUINAZOLIN-2-YL)ETHYL)AMINO)PYRIMIDINE-5-CARBONITRILE | GILEAD CALISTOGA LLC (US) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013082540-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | GILEAD CALISTOGA LLC (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20130143902-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | GILEAD CALISTOGA LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143902-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | GILEAD CALISTOGA LLC (US) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
| US-20130143902-A1 | COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE | TP53, KRAS, MKI67 | ITGB1 4388/4885ITGA4 4013/4885MAPT 1588/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
| US-20150225410-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
| US-20150111874-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ITGB1 3395/4885ITGA4 3977/4885MAPT 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.